An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-002320-29

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate progression free survival (PFS) with XL184 treatment as compared with placebo in subjects with unresectable, locally advanced or metastatic medullary thyroid carcinoma (MTC).


Critère d'inclusion

  • Medullary thyroid carcinoma (MTC)